Anti-tumor activity observed with nofazinlimab was comparable to that observed in studies of other single agent PD-1 inhibitors (e.g., nivolumab, pembrolizumab) in anti-PD-1/PD-L1-naïve populations with similar tumor types [24–28]. Here, CD274 is linked to neoplasm.